Peptide mimotopes as prototypic templates of broad-spectrum surrogates of carbohydrate antigens for cancer vaccination

Critical Reviews in Immunology

Volumn 27, Issue 3, 2007, Pages 247-270

  Pashov, Anastas ^a   Monzavi Karbassi, Behjatolah ^a   Raghava, Gajendra ^a   Kieber Emmons, Thomas ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Antigen recognition; Peptide mimics; Polyspecificity

Indexed keywords

ALPHA DEXTRO MANNOSYL 6 PHOSPHATE POLYACRYLAMIDE; ANTIBODY; CADMIUM SELENIDE; CARBOHYDRATE ANTIGEN; CARBOHYDRATE MIMETIC PEPTIDE 106; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; FUCOSYL ALPHA 1,3 N ACETYLGLUCOSAMINE; GLOBO H ANTIGEN; GLYCYLGLYCYLISOLEUCYLTYROSYLARGINYLTYROSYLASPARTYLISOLEUCYLTYROSYLTRYPTOPHYLARGINYLTYROSYLASPARTYLISOLEUCYLTYROSYLTRYPTOPHYLARGINYLTYROSYLASPARTIC ACID; GLYCYLGLYCYLISOLEUCYLTYROSYLTYROSYLARGINYLTYROSYLASPARTYLISOLEUCYLTYROSYLTYROSYLARGINYLTYROSYLASPARTYLISOLEUCYLTYROSYLTYROSYLARGINYLTYROSYLASPARTIC ACID; GLYCYLGLYCYLISOLEUCYLTYROSYLTYROSYLPROLYLTYROSYLASPARTYLISOLEUCYLTYROSYLTYROSYLPROLYLTYROSYLASPARTYLISOLEUCYLTYROSYLTYROSYLPROLYLTYROSYLASPARTIC ACID; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LEWIS Y ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E5; MULTIVALENT ANTIGENIC PEPTIDE 105; PEPTIDE MIMOTOPE; PEPTIDE VACCINE; POLYACRYLAMIDE; QUANTUM DOT; STN ANTIGEN; STREPTAVIDIN; TUMOR ASSOCIATED CARBOHYDRATE ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC SULFIDE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODY COMBINING SITE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMBINATORIAL LIBRARY; CONFERENCE PAPER; DRUG DESIGN; DRUG EFFECT; HUMAN; IMMUNOGENICITY; MEMORY T LYMPHOCYTE; MOLECULAR MIMICRY; NEOPLASM; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MOTIF;

EID: 38049049450     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.v27.i3.50     Document Type: Conference Paper

References (164)

1. Pietersz GA, Pouniotis DS, Apostolopoulos V. Design of peptide-based vaccines for cancer. Curr Med Chem. 2006;13(14):1591-607.
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-8.
3. Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother. 2006;55(11):1432-42.
4. Li G, Miles A, Line A, Rees RC. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother. 2004;53(3):139-43. Epub 2004 Jan 13.
5. Suri A. Cancer testis antigens - their importance in immunotherapy and in the early detection of cancer. Expert Opin Biol Ther. 2006;6(4):379-89.
6. Waldmann TA. Effective cancer therapy through immunomodulation. Annu Rev Med. 2006;57:65-81.
7. Radvanyi L. Discovery and immunologic validation of new antigens for therapeutic cancer vaccines. Int Arch Allergy Immunol. 2004;133(2):179-97. Epub 2004 Feb 5.
8. Ringel J, Lohr M. The MUC gene family: their role in diagnosis and early detection of pancreatic cancer. Mol Cancer. 2003;2:9.
9. Apostolopoulos V, McKenzie IF. Cellular mucins: targets for immunotherapy. Crit Rev Immunol. 1994;14(3-4):293-309.
10. Knuth A, Jager D, Jager E. Cancer immunotherapy in clinical oncology. Cancer Chemother Pharmacol. 2000;46(Suppl):S46-51.
11. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis. 2006;12(1):48-54.
12. Munoz ET, Deem MW. Epitope analysis for influenza vaccine design. Vaccine. 2005;23(9):1144-8.
13. Mariuzza RA. Multiple paths to multispecificity. Immunity. 2006;24(4):359-61.
14. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216.
15. Rallabhandi P, Bell J, Boukhvalova MS, Medvedev A, Lorenz E, Arditi M, Hemming VG, Blanco JCG, Segal DM, Vogel SN. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol. 2006;177(1):322-32.
16. Van Die I, Van Vliet SJ, Kwame Nyame A, Cummings RD, Bank CM, Appelmelk B, Geijtenbeek TB, Van Kooyk Y. The dendritic cell specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and recognizes the glycan antigen Lewis-x. Glycobiology. 2003;13(6):471-8.
17. Stebbing J, Savage P, Patterson S, Gazzard B. All for CD91 and CD91 for all. J Antimicrob Chemother. 2004;53(1):1-3.
18. McFarland BJ, Strong RK. Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation. Immunity. 2003;19(6):803-12.
19. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor [see comments]. Immunol Today. 1998;19(9):395-404.
20. Li Y, Huang Y, Lue J, Quandt JA, Martin R, Mariuzza RA. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J. 2005;24(17):2968-79.
21. Rousseau PG, Mallett CP, Smith-Gill SJ. A substantial proportion of the adult BALB/c available B cell repertoire consists of multireactive B cells. Mol Immunol. 1989;26(10):993-1006.
22. Manivel V, Bayiroglu F, Siddiqui Z, Salunke DM, Rao KVS. The primary antibody repertoire represents a linked network of degenerate antigen specificities. J Immunol. 2002;169(2):888-97.
23. Manivel V, Sahoo NC, Salunke DM, Rao KV. Maturation of an antibody response is governed by modulations in flexibility of the antigen-combining site. Immunity. 2000;13(5):611-20.
24. Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC. Structural insights into the evolution of an antibody combining site. Science. 1997;276(5319):1665-9.
25. Yin J, Beuscher AEt, Andryski SE, Stevens RC, Schultz PG. Structural plasticity and the evolution of antibody affinity and specificity. J Mol Biol. 2003;330(4):651-6.
26. Sethi DK, Agarwal A, Manivel V, Rao KV, Salunke DM. Differential epitope positioning within the germline antibody paratope enhances promiscuity in the primary immune response. Immunity. 2006;24(4):429-38.
27. Neuman Y. Meaning-making in the immune system. Perspect Biol Med. 2004;47(3):317-27.
28. Bousso P, Lemaitre F, Bilsborough J, Kourilsky P. Facing two T cell epitopes: a degree of randomness in the primary response is lost upon secondary immunization. J Immunol. 2000;165(2):760-7.
29. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Cancer Res. 1989;52:257-331.
30. Hakomori S. Possible functions of tumor-associated carbohydrate antigens. Current Opin Immunol. 1991;3:646-653.
31. Hakomori S, Zhang Y. Glycosphingolipid antigens and cancer therapy. Chem Biol. 1997;4(2):97-104.
32. Hakomori S. Traveling for the glycosphingolipid path. Glycoconj J 2000;17(7-9):627-47.
33. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A. 2002;99(16):10231-3. Epub 2002 Jul 30.
34. Ibrahim NK, Murray JL. Clinical development of the STn-KLH vaccine (Theratope). Clin Breast Cancer. 2003;3(Suppl 4):S139-43.
35. Dabelsteen E. Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol. 1996;179(4):358-69.
36. Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RF. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol. 1999;112(2):205-9.
37. Kieber-Emmons T, Luo P, Qiu J, Chang TY, O I, Blaszczyk-Thurin M, Steplewski Z. Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat Biotechnol. 1999;17(7):660-5.
38. Monzavi-Karbassi B, Artaud C, Jousheghany F, Hennings L, Carcel-Trullols J, Shaaf S, Korourian S, Kieber-Emmons T. Reduction of spontaneous metastases through induction of carbohydrate cross-reactive apoptotic antibodies. J Immunol. 2005;174(11):7057-65.
39. Monzavi-Karbassi B, Cunto-Amesty G, Luo P, Shamloo S, Blaszcyk-Thurin M, Kieber-Emmons T. Immunization with a carbohydrate mimicking peptide augments tumor-specific cellular responses. Int Immunol. 2001;13(11):1361-71.
40. Monzavi-Karbassi B, Luo P, Jousheghany F, Torres-Quinones M, Cunto-Amesty G, Artaud C, Kieber-Emmons T. A mimic of tumor rejection antigenassociated carbohydrates mediates an antitumor cellular response. Cancer Res. 2004;64(6):2162-6.
41. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24(22):4692-700. Epub 2006 Mar 31.
42. Vliegenthart JF. Carbohydrate based vaccines. FEBS Lett. 2006;580(12):2945-50. Epub 2006 Mar 29.
43. Verez-Bencomo V, Fernandez-Santana V, Hardy E, Toledo ME, Rodriguez MC, Heynngnezz L, Rodriguez A, Baly A, Herrera L, Izquierdo M, Villar A, Valdes Y, Cosme K, Deler ML, Montane M, Garcia E, Ramos A, Aguilar A, Medina E, Torano G, Sosa I, Hernandez I, Martinez R, Muzachio A, Carmenates A, Costa L, Cardoso F, Campa C, Diaz M, Roy R. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science. 2004;305(5683):522-5.
44. Houghton AN, Lloyd KO. Stuck in the MUC on the long and winding road [news; comment]. Nat Med. 1998;4(3):270-1.
45. Hurwitz AA, Ji Q. Autoimmune depigmentation following sensitization to melanoma antigens. Methods Mol Med. 2004;102:421-7.
46. Galili U. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol. 2005;83(6):674-86.
47. Preiss S, Kammertoens T, Lampert C, Willimsky G, Blankenstein T. Tumor-induced antibodies resemble the response to tissue damage. Int J Cancer. 2005;115(3):456-62.
48. Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol. 2005;174(9):5706-12.
49. Yoshida S, Kawaguchi H, Sato S, Ueda R, Furukawa K. An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation. Jpn J Cancer Res. 2002;93(7):816-24.
50. Aixinjueluo W, Furukawa K, Zhang Q, Hamamura K, Tokuda N, Yoshida S, Ueda R. Mechanisms for the apoptosis of small cell lung cancer cells induced by Anti-GD2 monoclonal antibodies: roles of anoikis. J Biol Chem. 2005;280(33):29828-29836. Epub 2005 May 26.
51. Retter MW, Johnson JC, Peckham DW, Bannink JE, Bangur CS, Dresser K, Cai F, Foy TM, Fanger NA, Fanger GR, Woda B, Rock KL. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts. Cancer Res. 2005;65(14):6425-34.
52. Nakamura K, Hanibuchi M, Yano S, Tanaka Y, Fujino I, Inoue M, Takezawa T, Shitara K, Sone S, Hanai N. Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized anti-ganglioside GM2 monoclonal antibody. Cancer Res. 1999;59(20):5323-30.
53. Vollmers HP, Brandlein S. The "early birds": natural IgM antibodies and immune surveillance. Histol Histopathol. 2005;20(3):927-37.
54. Guthmann MD, Bitton RJ, Carnero AJ, Gabri MR, Cinat G, Koliren L, Lewi D, Fernandez LE, Alonso DF, Gomez DE, Fainboim L. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity. J Immunother. 2004;27(6):442-51.
55. Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, Baez V, Livingston PO. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res. 2004;10(18 Pt 1):6094-100.
56. Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003;9(14):5214-20.
57. Krug LM, Ragupathi G, Ng KK, Hood C, Jennings HJ, Guo Z, Kris MG, Miller V, Pizzo B, Tyson L, Baez V, Livingston PO. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin Cancer Res. 2004;10(3):916-23.
58. Slovin SF, Ragupathi G, Fernandez C, Jefferson MP, Diani M, Wilton AS, Powell S, Spassova M, Reis C, Clausen H, Danishefsky S, Livingston P, Scher HI. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21. Vaccine. 2005;23(24):3114-22.
59. Sabbatini PJ, Kudryashov V, Ragupathi G, Danishefsky SJ, Livingston PO, Bornmann W, Spassova M, Zatorski A, Spriggs D, Aghajanian C, Soignet S, Peyton M, O'Flaherty C, Curtin J, Lloyd KO. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer. 2000;87(1):79-85.
60. Holmberg LA, Sandmaier BM. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev Vaccines. 2004;3(6):655-63.
61. Robbins JB, Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis. 1990;161:821-32.
62. Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980;152(2):361-76.
63. Goldblatt D. Recent developments in bacterial conjugate vaccines. J Med Microbiol. 1998;47(7):563-7.
64. McCool TL, Harding CV, Greenspan NS, Schreiber JR. B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. Infect Immun. 1999;67(9):4862-9.
65. Gilewski T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang XF, Bornmann WG, Spassova M, Bencsath KP, Panageas KS, Chin J, Hudis CA, Norton L, Houghton AN, Livingston PO, Danishefsky SJ. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A. 2001;98(6):3270-5.
66. Khan AQ, Lees A, Snapper CM. Differential regulation of IgG anti-capsular polysaccharide and antiprotein responses to intact Streptococcus pneumoniae in the presence of cognate CD4+ T cell help. J Immunol. 2004;172(1):532-9.
67. Meloen RH, Puijk WC, Slootstra JW. Mimotopes: realization of an unlikely concept. J Mol Recognit. 2000;13(6):352-9.
68. Partidos CD. Peptide mimotopes as candidate vaccines. Curr Opin Mol Ther. 2000;2(1):74-9.
69. Deroo S, Muller CP. Antigenic and immunogenic phage displayed mimotopes as substitute antigens: applications and limitations. Comb Chem High Throughput Screen. 2001;4(1):75-110.
70. Moe GR, Tan S, Granoff DM. Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease. FEMS Immunol Med Microbiol. 1999;26(3-4):209-26.
71. Westerink MAJ, Giardina PC, Apicella MA, Kieber-Emmons T. Peptide mimicry of the meningococcal group C capsular polysaccharide. Proc. Natl Acad Sci. 1995;92:4021-5.
72. Cunto-Amesty G, Luo P, Monzavi-Karbassi B, Lees A, Kieber-Emmons T. Exploiting molecular mimicry to broaden the immune response to carbohydrate antigens for vaccine development. Vaccine. 2001;19(17-19):2361-8.
73. Kieber-Emmons T, Monzavi-Karbassi B, Wang B, Luo P, Weiner DB. Cutting edge: DNA immunization with minigenes of carbohydrate mimotopes induce functional anti-carbohydrate antibody response. J Immunol. 2000;165(2):623-7.
74. Fleuridor R, Lees A, Pirofski L. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J Immunol. 2001;166(2):1087-96.
75. Qiu J, Luo P, Wasmund K, Steplewski Z, Kieber-Emmons T. Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines. Hybridoma. 1999;18(1):103-12.
76. Fukushi Y, Kannagi R, Hakomori S, Shepard T, Kulander BG, Singer JW. Location and distribution of difucoganglioside (VI3NeuAcV3III3Fuc2nLc6) in normal and tumor tissues defined by its monoclonal antibody FH6. Cancer Res. 1985;45(8):3711-7.
77. Luo P, Agadjanyan M, Qiu J, Westerink MA, Steplewski Z, Kieber-Emmons T. Antigenic and immunological mimicry of peptide mimotopes of Lewis carbohydrate antigens. Mol Immunol. 1998;35(13):865-79.
78. Monzavi-Karbassi B, Cunto-Amesty G, Luo P, Kieber-Emmons T. Peptide mimotopes as surrogate antigens of carbohydrates in vaccine discovery. Trends Biotechnol. 2002;20(5):207-14.
79. Scott JK, Loganathan D, Easley RB, Gong X, Goldstein IJ. A family of concanavalin A-binding peptides from a hexapeptide epitope library. Proc Natl Acad Sci U S A. 1992;89(12):5398-402.
80. Oldenburg KR, Loganathan D, Goldstein IJ, Schultz PG, Gallop MA. Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc Natl Acad Sci U S A. 1992;89(12):5393-7.
81. Mirkov TE, Evans SV, Wahlstrom J, Gomez L, Young NM, Chrispeels MJ. Location of the active site of the bean alpha-amylase inhibitor and involvement of a Trp, Arg, Tyr triad. Glycobiology. 1995;5(1):45-50.
82. Hoess R, Brinkmann U, Handel T, Pastan I. Identification of a peptide which binds to the carbohydratespecific monoclonal antibody B3. Gene. 1993;128(1):43-9.
83. Harris SL, Craig L, Mehroke JS, Rashed M, Zwick MB, Kenar K, Toone EJ, Greenspan N, Auzanneau FI, Marino AJ, Pinto BM, Scott JK. Exploring the basis of peptide-carbohydrate crossreactivity: evidence for discrimination by peptides between closely related anti-carbohydrate antibodies. Proc Natl Acad Sci U S A. 1997;94(6):2454-9.
84. Pashov A, Canziani G, Macleod S, Plaxco J, Monzavi-Karbassi B, Kieber-Emmons T. Targeting carbohydrate antigens in HIV vaccine development. Vaccine. 2005;23(17-18):2168-75.
85. Pashov AD, Plaxco J, Kaveri SV, Monzavi-Karbassi B, Harn D, Kieber-Emmons T. Multiple antigenic mimotopes of HIV carbohydrate antigens - relating structure and antigenicity. J Biol Chem. 2006;281(40):29675-83.
86. Luo P, Canziani G, Cunto-Amesty G, Kieber-Emmons T. A molecular basis for functional peptide mimicry of a carbohydrate antigen. J Biol Chem. 2000;275(21):16146-54 .
87. Kieber-Emmons T. Peptide mimotopes of carbohydrate antigens. Immunol Res. 1998;17:95-108.
88. Kieber-Emmons T, Luo P, Qiu J, Agadjanyan M, Carey L, Hutchins W, Westerink MA, Steplewski Z. Peptide mimicry of adenocarcinoma-associated carbohydrate antigens. Hybridoma. 1997;16(1):3-10.
89. Agadjanyan M, Luo P, Westerink MA, Carey LA, Hutchins W, Steplewski Z, Weiner DB, Kieber-Emmons T. Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus [see comments]. Nat Biotechnol. 1997;15(6):547-51.
90. Cunto-Amesty G, Dam TK, Luo P, Monzavi-Karbassi B, Brewer CF, Van Cott TC, Kieber-Emmons T. Directing the immune response to carbohydrate antigens. J Biol Chem. 2001;276(32):30490-8.
91. Prinz DM, Smithson SL, Kieber-Emmons T, Westerink MA. Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide. Immunology. 2003;110(2):242-9.
92. Monzavi-Karbassi B, Shamloo S, Kieber-Emmons M, Jousheghany F, Luo P, Lin KY, Cunto-Amesty G, Weiner DB, Kieber-Emmons T. Priming characteristics of peptide mimotopes of carbohydrate antigens. Vaccine. 2003;21(7-8):753-60.
93. Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res. 2003;338(23):2539-47.
94. Lindroth K, Mastache EF, Roos I, Fernandez AG, Fernandez C. Understanding thymus-independent antigen-induced reduction of thymus-dependent immune responses. Immunology. 2004;112(3):413-9.
95. Sanchez M, Lindroth K, Sverremark E, Gonzalez Fernandez A, Fernandez C. The response in old mice: positive and negative immune memory after priming in early age. Int Immunol. 2001;13(10):1213-21.
96. Kudryashov V, Glunz PW, Williams LJ, Hintermann S, Danishefsky SJ, Lloyd KO. Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice. Proc Natl Acad Sci U S A. 2001;98(6):3264-9.
97. Song H, Cerny J. Functional heterogeneity of marginal zone B cells revealed by their ability to generate both early antibody-forming cells and germinal centers with hypermutation and memory in response to a T-dependent antigen. J Exp Med. 2003;198(12):1923-35.
98. Alugupalli KR, Leong JM, Woodland RT, Muramatsu M, Honjo T, Gerstein RM. B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity. 2004;21(3):379-90.
99. de Vinuesa CG, Cook MC, Ball J, Drew M, Sunners Y, Cascalho M, Wabl M, Klaus GG, MacLennan IC. Germinal centers without T cells. J Exp Med. 2000;191(3):485-94.
100. Newman J, Rice JS, Wang C, Harris SL, Diamond B. Identification of an antigen-specific B cell population. J Immunol Methods. 2003;272(1-2):177-87.
101. Watson A, Wu X, Bruchez M. Lighting up cells with quantum dots. Biotechniques. 2003;34(2):296-300, 302-3.
102. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature. 2005;435(7042):590-7.
103. Rubinstein LJ, Garcia-Ojeda PA, Michon F, Jennings HJ, Stein KE. Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine. Infect Immunol. 1998;66(11):5450-6.
104. Cunto-Amesty G, Luo P, Monzavi-Karbassi B, Lees A, Alexander J, del Guercio MF, Nahm MH, Artaud C, Stanley J, Kieber-Emmons T. Peptide mimotopes as prototypic templates of broad-spectrum surrogates of carbohydrate antigens. Cell Mol Biol (Noisy-legrand). 2003;49(2):245-54.
105. Notkins AL. Polyreactivity of antibody molecules. Trends Immunol 2004;25(4):174-9.
106. Westhof E, Altschuh D, Moras D, Bloomer AC, Mondragon A, Klug A, Van Regenmortel MH. Correlation between segmental mobility and the location of antigenic determinants in proteins. Nature. 1984;311(5982):123-6.
107. Margulies DH. Molecular interactions: stiff or floppy (or somewhere in between?). Immunity. 2003;19(6):772-4.
108. James LC, Roversi P, Tawfik DS. Antibody multispecificity mediated by conformational diversity. Science. 2003;299(5611):1362-7.
109. Bosshard HR. Molecular recognition by induced fit: how fit is the concept? News Physiol Sci. 2001;16:171-3.
110. Berger C, Weber-Bornhauser S, Eggenberger J, Hanes J, Pluckthun A, Bosshard HR. Antigen recognition by conformational selection. FEBS Lett. 1999;450(1-2):149-53.
111. Fischer E. Einfluss der Configuration auf die Wirkung der Enzyme. Ber Dtsch Chem Ges. 1894;27:2984-93.
112. Koshland DE. Application of a theory of enzyme specificity to protein synthesis. Proc Natl Acad Sci U S A. 1958;44(2):98-104.
113. Leder L, Berger C, Bornhauser S, Wendt H, Ackermann F, Jelesarov I, Bosshard HR. Spectroscopic, calorimetric, and kinetic demonstration of conformational adaptation in peptide-antibody recognition. Biochemistry. 1995;34(50):16509-18.
114. Durr E, Bosshard HR. A monoclonal antibody induces opening of a coiled coil. Global protection of amide protons from H/D exchange decreases by up to 1000-fold in antibody-bound triple-stranded coiled coil. Eur J Biochem. 1997;249(1):325-9.
115. Mello MA, Mascarenhas RE, Ferraro GA, Harn D, Galvao-Castro M, Bou-Habib DC. Inhibition of HIV-1 infection by monoclonal antibodies to carbohydrates of Schistosoma mansoni. Med Microbiol Immunol (Berl). 2005;194(1-2):61-5.
116. Ko AI, Drager UC, Harn DA. A Schistosoma mansoni epitope recognized by a protective monoclonal antibody is identical to the stage-specific embryonic antigen 1. Proc Natl Acad Sci U S A. 1990;87(11):4159-63.
117. Pashov A, Perry M, Dyar M, Chow M, Kieber-Emmons T. Carbohydrate mimotopes in the rational design of cancer vaccines. Curr Top Med Chem. 2005;5(12):1171-85.
118. Ghiara JB, Ferguson DC, Satterthwait AC, Dyson HJ, Wilson IA. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site. J Mol Biol. 1997;266(1):31-9.
119. Young AC, Valadon P, Casadevall A, Scharff MD, Sacchettini JC. The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage display library: implications for the identification of peptide mimotopes. J Mol Biol. 1997;274(4):622-34.
120. Murali R, Kieber-Emmons T. Molecular recognition of a peptide mimic of the Lewis Y antigen by an anti-Lewis Y antibody. J Mol Recognit. 1997;10(6):269-76.
121. James LC, Tawfik DS. The specificity of cross-reactivity: promiscuous antibody binding involves specific hydrogen bonds rather than nonspecific hydrophobic stickiness. Protein Sci. 2003;12(10):2183-93.
122. van Regenmortel MH. Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure-function relationships in immunology. Vaccine. 1999;18(3-4):216-21.
123. Evans SV, Rose DR, To R, Young NM, Bundle DR. Exploring the mimicry of polysaccharide antigens by anti-idiotypic antibodies. The crystallization, molecular replacement, and refinement to 2.8 A resolution of an idiotope-anti-idiotope Fab complex and of the unliganded anti-idiotope Fab. J Mol Biol. 1994;241(5):691-705.
124. Young NM, Gidney MA, Gudmundsson BM, MacKenzie CR, To R, Watson DC, Bundle DR. Molecular basis for the lack of mimicry of Brucella polysaccharide antigens by Ab2gamma antibodies. Mol Immunol. 1999;36(6):339-47.
125. Transue TR, De Genst E, Ghahroudi MA, Wyns L, Muyldermans S. Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate. Proteins. 1998;32(4):515-22.
126. Thompson LW, Garbee CF, Hibbitts S, Brinckerhoff LH, Pierce RA, Chianese-Bullock KA, Deacon DH, Engelhard VH, Slingluff CL, Jr. Competition among peptides in melanoma vaccines for binding to MHC molecules. J Immunother. 2004;27(6):425-31.
127. Sette A, Sidney J, del Guercio MF, Southwood S, Ruppert J, Dahlberg C, Grey HM, Kubo RT. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol. 1994;31(11):813-22.
128. Rudolph MG, Wilson IA. The specificity of TCR/pMHC interaction. Curr Opin Immunol. 2002;14(1):52-65.
129. Sandberg J, Franksson L, Sundback J, Michaelsson J, Petersson M, Achour A, Wallin R, Sherman N, Bergman T, Jornvall H, Hunt D, Kiessling R, Karre K. T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J Immunol. 2000;165(1):25-33.
130. Abdel-Motal U, Berg L, Rosen A, Bengtsson M, Thorpe CJ, Kihlberg J, Dahmen J, Magnusson G, Karlsson KA, Jondal M. Immunization with glycosylated Kb-binding peptides generates carbohydratespecific, unrestricted cytotoxic T cells. Eur J Immunol. 1996;26(3):544-51.
131. Butenhof KJ, Gerken TA. Structure and dynamics of mucin-like glycopeptides. Examination of peptide chain expansion and peptide-carbohydrate interactions by stochastic dynamics simulations. Biochemistry. 1993;32(10):2650-63.
132. Carbone FR, Gleeson PA. Carbohydrates and antigen recognition by T cells. Glycobiology 1997;7(6):725-30.
133. Chong P, Chan N, Kandil A, Tripet B, James O, Yang YP, Shi SP, Klein M. A strategy for rational design of fully synthetic glycopeptide conjugate vaccines. Infect Immun. 1997;65(12):4918-25.
134. Dudler T, Altmann F, Carballido JM, Blaser K. Carbohydrate-dependent, HLA class II-restricted, human T cell response to the bee venom allergen phospholipase A2 in allergic patients. Eur J Immunol. 1995;25(2):538-42.
135. Galli-Stampino L, Meinjohanns E, Frische K, Meldal M, Jensen T, Werdelin O, Mouritsen S. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res. 1997;57(15):3214-22.
136. Glithero A, Tormo J, Haurum JS, Arsequell G, Valencia G, Edwards J, Springer S, Townsend A, Pao YL, Wormald M, Dwek RA, Jones EY, Elliott T. Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Immunity. 1999;10(1):63-74.
137. Haurum JS, Arsequell G, Lellouch AC, Wong SY, Dwek RA, McMichael AJ, Elliott T. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med. 1994;180(2):739-44.
138. Haurum JS, Tan L, Arsequell G, Frodsham P, Lellouch AC, Moss PA, Dwek RA, McMichael AJ, Elliott T. Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition. Eur J Immunol. 1995;25(12):3270-6.
139. Haurum JS, Hoier IB, Arsequell G, Neisig A, Valencia G, Zeuthen J, Neefjes J, Elliott T. Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med. 1999;190(1):145-50.
140. Jensen T, Galli SL, Mouritsen S, Frische K, Peters S, Meldal M, Werdelin O. T cell recognition of Tn-glycosylated peptide antigens. Eur J Immunol. 1996;26(6):1342-9.
141. Jensen T, Hansen P, Galli SL, Mouritsen S, Frische K, Meinjohanns E, Meldal M, Werdelin O. Carbohydrate and peptide specificity of MHC class II-restricted T cell hybridomas raised against an O-glycosylated self peptide. J Immunol. 1997;158(8):3769-78.
142. Kastrup IB, Stevanovic S, Arsequell G, Valencia G, Zeuthen J, Rammensee HG, Elliott T, Haurum JS, Sun Y, Hwang Y, Nahm MH. Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo. Tissue Antigens. 2000;56(2):129-35.
143. Lo-Man R, Vichier-Guerre S, Bay S, Deriaud E, Cantacuzene D, Leclerc C. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J Immunol. 2001;166(4):2849-54.
144. Michaelsson E, Broddefalk J, Engstrom A, Kihlberg J, Holmdahl R. Antigen processing and presentation of a naturally glycosylated protein elicits major histocompatibility complex class II-restricted, carbohydratespecific T cells. Eur J Immunol. 1996;26(8):1906-10.
145. Prammer KV, Ertl HC, Otvos L Jr. Computer design of T-cell agonist or antagonist glycopeptides: the effect of sugar identity and anomeric configuration on MHC binding. Biomed Pept Proteins Nucleic Acids. 1995;1(3):163-70.
146. Speir JA, Abdel-Motal UM, Jondal M, Wilson IA. Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity. 1999;10(1):51-61.
147. Werdelin O, Meldal M, Jensen T. Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells. Proc Natl Acad Sci U S A. 2002;99(15):9611-3.
148. Franco A. CTL-based cancer preventive/therapeutic vaccines for carcinomas: role of tumour-associated carbohydrate antigens. Scand J Immunol. 2005;61(5):391-7.
149. Xu Y, Gendler SJ, Franco A. Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J Exp Med. 2004;199(5):707-16.
150. Rock KL, Rothstein L, Benacerraf B. Analysis of the association of peptides of optimal length to class I molecules on the surface of cells. Proc Natl Acad Sci U S A 1992;89(19):8918-22.
151. Stepensky D, Tzehoval E, Vadai E, Eisenbach L. Oglycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin Exp Immunol. 2006;143(1):139-49.
152. Bhasin M, Raghava GP. Prediction of promiscuous and high-affinity mutated MHC binders. Hybrid Hybridomics. 2003;22(4):229-34.
153. Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogenbonded and geometrical features. Biopolymers. 1983;22(12):2577-637.
154. Hutchins WA, Adkins AR, Kieber-Emmons T, Westerink MA. Molecular characterization of a monoclonal antibody produced in response to a group C meningococcal polysaccharide peptide mimic. Mol Immunol. 1996;33(6):503-10.
155. Valadon P, Nussbaum G, Oh J, Scharff MD. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide. J Immunol. 1998;161(4):1829-36.
156. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med. 1993;178(1):27-47.
157. Chicz RM, Lane WS, Robinson RA, Trucco M, Strominger JL, Gorga JC. Self-peptides bound to the type I diabetes associated class II MHC molecules HLA-DQ1 and HLA-DQ8. INT IMMUNOL. Int Immunol. 1994;6(11):1639-49.
158. Dengjel J, Rammensee HG, Stevanovic S. Glycan side chains on naturally presented MHC class II ligands. J Mass Spectrom. 2005;40(1):100-4.
159. Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R. T cell recognition of carbohydrates on type II collagen. J Exp Med. 1994;180(2):745-9.
160. Backlund J, Carlsen S, Hoger T, Holm B, Fugger L, Kihlberg J, Burkhardt H, Holmdahl R. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2002;99(15):9960-5.
161. Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L, Jr., Hanisch F-G, Finn OJ. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen muc1 glycopeptides for presentation to major histocompatibility complex class II-restricted T Cells. J. Exp. Med. 2002;196(11):1435-46.
162. Apostolopoulos V, Yuriev E, Ramsland PA, Halton J, Osinski C, Li W, Plebanski M, Paulsen H, McKenzie IF. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci U S A. 2003;100(25):15029-34.
163. Stepensky D, Tzehoval E, Vadai E, Eisenbach L. Oglycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin Exp Immunol. 2006;143 (1):139-49.
164. Gritzapis AD, Perez SA, Baxevanis CN, Papamichail M. Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo. Br J Cancer. 2005;92(1):72-9.